Piper Sandler Reaffirms Their Buy Rating on Inovio Pharmaceuticals (INO)
In a report released today, Edward Tenthoff from Piper Sandler reiterated a Buy rating on Inovio Pharmaceuticals, with a price target of $6.00.
Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Tenthoff covers the Healthcare sector, focusing on stocks such as Capricor Therapeutics, Moderna, and Alnylam Pharma. According to TipRanks, Tenthoff has an average return of 0.7% and a 39.14% success rate on recommended stocks.
The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Inovio Pharmaceuticals with a $7.33 average price target.
Based on Inovio Pharmaceuticals’ latest earnings release for the quarter ending September 30, the company reported a quarterly GAAP net loss of $45.5 million. In comparison, last year the company had a GAAP net loss of $25.17 million
Read More on INO:
Disclaimer & DisclosureReport an Issue
- Balanced View on INOVIO’s INO-3107: Strong Long-Term Data Offset by Regulatory and Timing Uncertainty Driving Hold Rating
- FDA Accepts Inovio’s BLA for INO-3107 Review
- Inovio announces U.S. FDA accepted BLA for INO-3107
- Inovio Pharmaceuticals: Hold Rating Amid Financial Challenges and Pending Regulatory Milestones
- Inovio price target raised to $6 from $5 at Piper Sandler
